Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H10FN3O4 |
Molecular Weight | 279.2239 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)[C@@H]1C[C@]2(NC(=O)NC2=O)C3=C(O1)C=CC(F)=C3
InChI
InChIKey=WAAPEIZFCHNLKK-UFBFGSQYSA-N
InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12-/m0/s1
Molecular Formula | C12H10FN3O4 |
Molecular Weight | 279.2239 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19748287Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18165015 | https://www.ncbi.nlm.nih.gov/pubmed/11574441 | https://www.ncbi.nlm.nih.gov/pubmed/26163626
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19748287
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18165015 | https://www.ncbi.nlm.nih.gov/pubmed/11574441 | https://www.ncbi.nlm.nih.gov/pubmed/26163626
Fidarestat (SNK-860) is an aldose reductase inhibitor codeveloped by Sanwa Kagaku, NK Curex, and Sankyo for the treatment of distal symmetric polyneuropathy (DSP). In a Phase III trial, 279 patients with DSP were randomized to receive fidarestat (1 mg daily) or placebo for 52 weeks. Evaluation of efficacy was based on changes in clinical symptoms (numbness, pain, rigidity, alterations in temperature perception, paresthesia, hypesthesia, and weakness) as well as changes in electrophysiological measurements such as F-wave NCV. Five of six electrophysiological measures assessing function in motor nerves showed statistically significant improvement from baseline within the treatment group; a comparison of the placebo and treatment groups on these measures, however, showed the statistical difference on only two of the six measures. Two electrophysiological measures of sensory function failed to show a statistically significant difference from baseline in the fidarestat group. Statistically significant improvements over placebo were noted on several measures of subjective symptoms (e.g., numbness of upper extremities, decreased tactile sensitivity in lower extremities, paresthesia in the sole), with a greater divergence between the two groups associated with the duration of treatment. The incidence of adverse events was 5.8% in the fidarestat group and 5% in the placebo group and no serious adverse events were noted.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1900 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18165015 |
9.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
High glucose-induced activation of the polyol pathway and changes of gene expression profiles in immortalized adult mouse Schwann cells IMS32. | 2006 Jul |
|
Characterization of a rat NADPH-dependent aldo-keto reductase (AKR1B13) induced by oxidative stress. | 2009 Mar 16 |
|
Aldose reductase inhibition prevents metaplasia of airway epithelial cells. | 2010 Dec 28 |
|
Amelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, fidarestat. | 2012 |
|
X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. | 2013 Feb 25 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11574441
A total of 279 patients with diabetic neuropathy were treated with placebo or fidarestat at a daily dose of 1 mg for 52 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26163626
HT-29 and SW480 colorectal cancer cells were rinsed with glucose-free RPMI-1640, followed by incubation in GD medium in the presence and/or absence of AR inhibitor Fidarestat (10μM). It was strictly ensured that the cells in culture were free from any suspected mycoplasma and/or endotoxin contamination prior to conducting cell-treatments and protein extraction as part of the current exploratory study.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:25:12 UTC 2023
by
admin
on
Fri Dec 15 16:25:12 UTC 2023
|
Record UNII |
8SH8T1164U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C72880
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m5377
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | Merck Index | ||
|
7709
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
DTXSID4046654
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
160024
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
DB02021
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
SUB07624MIG
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
C077139
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
FIDARESTAT
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
C81355
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
105300-43-4
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
136087-85-9
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
8SH8T1164U
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
CHEMBL84446
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY | |||
|
100000080967
Created by
admin on Fri Dec 15 16:25:12 UTC 2023 , Edited by admin on Fri Dec 15 16:25:12 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |